Adam P Bress, Tom Greene, Catherine G Derington, Jincheng Shen, Yizhe Xu, Yiyi Zhang, Jian Ying, Brandon K Bellows, William C Cushman, Paul K Whelton, Nicholas M Pajewski, David Reboussin, Srinivasan Beddu, Rachel Hess, Jennifer S Herrick, Zugui Zhang, Paul Kolm, Robert W Yeh, Sanjay Basu, William S Weintraub, Andrew E Moran
BACKGROUND: Intensive systolic blood pressure (SBP) treatment prevents cardiovascular disease (CVD) events in patients with high CVD risk on average, though benefits likely vary among patients. OBJECTIVES: The aim of this study was to predict the magnitude of benefit (reduced CVD and all-cause mortality risk) along with adverse event (AE) risk from intensive versus standard SBP treatment. METHODS: This was a secondary analysis of SPRINT (Systolic Blood Pressure Intervention Trial)...
April 27, 2021: Journal of the American College of Cardiology